ABCG2 is highly expressed in several drug-resistant cancer cells, where it actively effluxes chemotherapeutic agents, such as mitoxantrone, topotecan, and anthracyclines, thereby reducing their intracellular accumulation and limiting their cytotoxic effects. This evidence concerns the gene ABCG2 and cancer.